Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Liabilities and Shareholders Equity (2017 - 2026)

Bioceres Crop Solutions' Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $529.6 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity changed N/A to $529.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.1 billion, a 1.97% decrease, with the full-year FY2025 number at $763.6 million, down 10.43% from a year prior.
  • Liabilities and Shareholders Equity hit $529.6 million in Q1 2026 for Bioceres Crop Solutions, down from $763.6 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BIOX hit a ceiling of $852.5 million in Q2 2024 and a floor of $518.2 million in Q2 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $696.4 million across 5 years, with a median of $763.6 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 57.86% in 2023 and later decreased 10.43% in 2025.
  • Tracing BIOX's Liabilities and Shareholders Equity over 5 years: stood at $518.2 million in 2022, then surged by 57.86% to $818.1 million in 2023, then increased by 4.22% to $852.5 million in 2024, then fell by 10.43% to $763.6 million in 2025, then crashed by 30.64% to $529.6 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for BIOX at $529.6 million in Q1 2026, $763.6 million in Q2 2025, and $852.5 million in Q2 2024.